Xeris Biopharma Holdings, Inc. Quarterly Interest Expense in USD from Q3 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Xeris Biopharma Holdings, Inc. quarterly/annual Interest Expense history and growth rate from Q3 2020 to Q1 2024.
  • Xeris Biopharma Holdings, Inc. Interest Expense for the quarter ending March 31, 2024 was $7.03M, a 13.1% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. Interest Expense for the twelve months ending March 31, 2024 was $27.4M, a 63.3% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. annual Interest Expense for 2023 was $26.6M, a 88.7% increase from 2022.
  • Xeris Biopharma Holdings, Inc. annual Interest Expense for 2022 was $14.1M, a 96.4% increase from 2021.
  • Xeris Biopharma Holdings, Inc. annual Interest Expense for 2021 was $7.18M, a 32.6% decline from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $27.4M $7.03M +$816K +13.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $26.6M $7.02M +$3.87M +123% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $22.7M $6.85M +$2.86M +71.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $19.9M $6.53M +$3.08M +89.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $16.8M $6.22M +$2.7M +76.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $14.1M $3.14M +$1.35M +75.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $12.8M $3.99M +$2.19M +122% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $10.6M $3.45M +$1.65M +92.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $8.91M $3.52M +$1.73M +96.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $7.18M $1.8M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $1.8M -$530K -22.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $1.8M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $1.79M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q3 2020 $2.33M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.